The purpose of this study is to determine the effect of rosiglitazone on the genes of the colon

The primary aim of the study is to examine the effect of rosiglitazone (Avandia) on gene regulation in colonic epithelium in the absence of pathologic acute and chronic intestinal inflammation. The secondary aims are to determine the effect of rosiglitazone (Avandia) therapy on T cell activation and cytokine expression in the absence of pathologic acute and chronic intestinal inflammation.

Inclusion Criteria:

• Capable of giving informed consent
• Agrees to use a barrier method of birth control for the duration of the study

Exclusion Criteria:

• History of inflammatory bowel disease
• Has taken prescription or over the counter medications in the two weeks prior to enrollment
• History of diabetes, heart failure, angina, hypertension, coronary heart disease, cancer, bleeding disorder, HIV, AIDS
• Fasting LDL >160 mg/dl
• History of smoking in the year prior to enrollment
• Pregnant or breastfeeding

Adverse events were collected at baseline and during follow-up for up to 30 days after the last administration of study drug.